Latest Press Releases View all Oct 09, 2026 Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference Oct 07, 2026 Vertex to Announce Third Quarter 2026 Financial Results November 2nd Sep 22, 2026 Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial View all Featured Media Library Items View all Reshma Kewalramani, M.D. Chief Executive Officer and President Download Duncan McKechnie Executive Vice President and Chief Commercial Officer Download Vertex International Headquarters – Lobby Download View all
Oct 09, 2026 Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Sep 22, 2026 Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial